• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CNS Pharmaceuticals, Inc. - Common Stock (NQ:CNSP)

9.200 -0.290 (-3.06%)
Streaming Delayed Price Updated: 3:59 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CNS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
21 22 Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
January 24, 2024
 
Via Benzinga
Novel Brain Scan Technique Exposes Vulnerability of Gliomas
January 23, 2024
Via Investor Brand Network
12 Health Care Stocks Moving In Monday's Intraday Session
January 22, 2024
 
Via Benzinga
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Names Seasoned Biotech Leader to Board of Directors
January 19, 2024
Via Investor Brand Network
Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors
January 18, 2024
Via ACCESSWIRE
CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin
December 18, 2023
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's After-Market Session
January 18, 2024
 
Via Benzinga
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reaches Planned Enrollment Berubicin Study for the Treatment of GBM
January 18, 2024
Via Investor Brand Network
CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
January 17, 2024
Via ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's After-Market Session
January 16, 2024
 
Via Benzinga
Multidisciplinary Consortium Sets Sights on Developing AI to Detect Gliomas
January 10, 2024
Via Investor Brand Network
Topics Artificial Intelligence
Light, Viruses Could Transform Brain-Tumor Treatment
December 28, 2023
Via Investor Brand Network
12 Health Care Stocks Moving In Monday's After-Market Session
December 18, 2023
 
Via Benzinga
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces DSMB Recommendation to Continue Pivotal GBM Study without Modification
December 18, 2023
Via Investor Brand Network
Researchers Discuss How Brain Cancer Radiotherapy Side Effects Can Be Reduced
December 15, 2023
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Interim Analysis on Global Berubicin Trial Showing Promising Results
December 06, 2023
Via Investor Brand Network
Topics Death
How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure
December 06, 2023
Via ACCESSWIRE
How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure
December 05, 2023
Every form of cancer is devastating, but the unfortunate reality is not all cancers are created equal. There are certain forms that are more deadly, with Glioblastoma (GBM) being one of the worst. GBM... 
Via Benzinga
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Presents Updated Safety Data from Berubicin Study at SNO Annual Gathering
November 22, 2023
Via Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy
November 22, 2023
Via ACCESSWIRE
Study Finds DNA Loops in Brain Tumors in Kids Amplify Relapse Risk
November 21, 2023
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Release Interim Data by Year End for Lead Treatment Candidate Berubicin
November 16, 2023
Via Investor Brand Network
Topics Death
CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate
November 16, 2023
Via ACCESSWIRE
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Q3 2023 Financial Results, Update on Berubicin Study
November 15, 2023
Via Investor Brand Network
CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate
November 15, 2023
Glioblastoma is a highly aggressive type of brain cancer with no cure, leading to a grim prognosis and average survival time of only 14 to 16 months. With no approved treatment for recurrent GBM... 
Via Benzinga
CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End
November 15, 2023
Via ACCESSWIRE
Brain Cancer Reemergence Could Soon Be Detected Using a Finger-Prick Test
November 09, 2023
Via Investor Brand Network
Stanford Study Finds Lung Cancer Cells Hide, Thrive in the Brain
October 27, 2023
Via Investor Brand Network
Spanish Clinical Trial to Explore Marijuana as Glioblastoma Treatment
October 24, 2023
Via Investor Brand Network
Topics Cannabis
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advancing Drive Toward Potential New GBM Treatment
October 20, 2023
Via Investor Brand Network
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
21 22 Next >
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap